|Bid||4.00 x 1000|
|Ask||7.95 x 1100|
|Day's Range||4.05 - 4.15|
|52 Week Range||3.25 - 5.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 6, 2018 - Feb 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.80|
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 08, 2018-- Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies ...
Achroma Corp., a non-profit 501(c)(3) tax-exempt charity dedicated to raising awareness and finding a cure for a rare form of blindness called Achromatopsia, announced results of a new global survey, Understanding the Achromatopsia Patient Experience. NASDAQ: AGTC), the gene therapy company, was distributed through Achroma Corp’s network and received 226 responses from individuals who have been diagnosed – or have a child who has been diagnosed – with Achromatopsia, a rare inherited retinal disorder that is associated with a significant reduction in visual acuity, extreme light sensitivity causing day blindness, and complete loss of color discrimination.
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has enrolled the first patient of the second cohort in the company’s Phase 1/2 clinical trial evaluating the safety and efficacy of an investigational AAV-based gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP). Under the terms of its collaboration with Biogen (BIIB), AGTC will receive a milestone payment of $10 million.
20+ Year Medical Affairs and Ophthalmology Veteran, Lanita C. Scott, M.D., Appointed as Vice President of Clinical Research and Medical Affairs. Karen M. Carroll, RN, Named Vice President of Clinical Development ...
The Alachua, Florida-based company said it had a loss of 45 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Stock Monitor: Applied Genetic Technologies Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 12, 2018 / Active-Investors.com has just released a free research report on Catalyst Biosciences, ...
The Alachua, Florida-based company said it had a loss of 29 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
NEW YORK, NY / ACCESSWIRE / February 9, 2018 / Applied Genetic Technologies Corp. (NASDAQ: AGTC ) will be discussing their earnings results in their Q2 Earnings Call to be held on February 9, 2018 at 8:00 ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Applied Genetic Technologies Corp. Here are 5 ETFs with the largest exposure to AGTC-US. Comparing the performance and risk of Applied Genetic Technologies Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Applied Genetic Technologies Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Applied Genetic Technologies Corp. – bluebird bio, Inc., Organovo Holdings, Inc., Eiger BioPharmaceuticals, Inc., Apollo Endosurgery, Inc. and Dicerna Pharmaceuticals, Inc. (BLUE-US, ONVO-US, EIGR-US, APEN-US and DRNA-US) ... Read more (Read more...)
Applied Genetic Technologies Corporation (NASDAQ:AGTC) is trading with a trailing P/E of 153.2x, which is higher than the industry average of 26.9x. While AGTC might seem like a stock toRead More...